These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38912898)

  • 1. Association of Complement Factors With Disability Progression in Primary Progressive Multiple Sclerosis.
    Lunemann JD; Hegen H; Villar LM; Rejdak K; Sao-Aviles A; Carbonell-Mirabent P; Sastre-Garriga J; Mongay-Ochoa N; Berek K; Martínez-Yélamos S; Pérez-Miralles F; Abdelhak A; Bachhuber F; Tumani H; Lycke JN; Rosenstein I; Alvarez-Lafuente R; Castillo-Trivino T; Otaegui D; Llufriu S; Blanco Y; Sánchez López AJ; Garcia Merino JA; Fissolo N; Gutierrez L; Villacieros-Álvarez J; Monreal E; Valls-Carbó A; Wiendl H; Montalban X; Comabella M
    Neurol Neuroimmunol Neuroinflamm; 2024 Jul; 11(4):e200270. PubMed ID: 38912898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased ratios of complement factors C3a to C3 in aqueous humor and serum mark glaucoma progression.
    Hubens WHG; Beckers HJM; Gorgels TGMF; Webers CAB
    Exp Eye Res; 2021 Mar; 204():108460. PubMed ID: 33493474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement Activation Is Associated With Disease Severity in Multiple Sclerosis.
    Oechtering J; Stein K; Schaedelin SA; Maceski AM; Orleth A; Meier S; Willemse E; Qureshi F; Heijnen I; Regeniter A; Derfuss T; Benkert P; D'Souza M; Limberg M; Fischer-Barnicol B; Achtnichts L; Mueller S; Salmen A; Lalive PH; Bridel C; Pot C; Du Pasquier RA; Gobbi C; Wiendl H; Granziera C; Kappos L; Trendelenburg M; Leppert D; Lunemann JD; Kuhle J;
    Neurol Neuroimmunol Neuroinflamm; 2024 Mar; 11(2):e200212. PubMed ID: 38354323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF chitinase 3-like-1 association with disability of primary progressive MS.
    Pérez-Miralles F; Prefasi D; García-Merino A; Gascón-Giménez F; Medrano N; Castillo-Villalba J; Cubas L; Alcalá C; Gil-Perotín S; Gómez-Ballesteros R; Maurino J; Álvarez-García E; Casanova B
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32611760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement activation in cerebrospinal fluid in clinically isolated syndrome and early stages of relapsing remitting multiple sclerosis.
    Håkansson I; Ernerudh J; Vrethem M; Dahle C; Ekdahl KN
    J Neuroimmunol; 2020 Mar; 340():577147. PubMed ID: 31951875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSF Chitinase 3-Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis.
    Comabella M; Sastre-Garriga J; Borras E; Villar LM; Saiz A; Martínez-Yélamos S; García-Merino JA; Pinteac R; Fissolo N; Sánchez López AJ; Costa-Frossard L; Blanco Y; Llufriu S; Vidal-Jordana A; Sabidó E; Montalban X
    Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34497102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.
    Hughes J; Jokubaitis V; Lugaresi A; Hupperts R; Izquierdo G; Prat A; Girard M; Duquette P; Grand'Maison F; Grammond P; Sola P; Ferraro D; Ramo-Tello C; Trojano M; Slee M; Shaygannejad V; Boz C; Lechner-Scott J; Van Pesch V; Pucci E; Solaro C; Verheul F; Terzi M; Granella F; Spitaleri D; Alroughani R; Jun JK; Fambiatos A; Van der Walt A; Butzkueven H; Kalincik T;
    JAMA Neurol; 2018 Nov; 75(11):1407-1415. PubMed ID: 30083762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lower level of complement component C3 and C3a in the plasma means poor outcome in the patients with hepatitis B virus related acute-on-chronic liver failure.
    Li Q; Lu Q; Zhu MQ; Huang C; Yu KK; Huang YX; Zhao X; Luo XG; Zheng JM
    BMC Gastroenterol; 2020 Apr; 20(1):106. PubMed ID: 32293297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry.
    Teunissen CE; Koel-Simmelink MJ; Pham TV; Knol JC; Khalil M; Trentini A; Killestein J; Nielsen J; Vrenken H; Popescu V; Dijkstra CD; Jimenez CR
    Mult Scler; 2011 Jul; 17(7):838-50. PubMed ID: 21505015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit.
    Silber E; Semra YK; Gregson NA; Sharief MK
    Neurology; 2002 May; 58(9):1372-81. PubMed ID: 12011283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF Levels of CXCL12 and Osteopontin as Early Markers of Primary Progressive Multiple Sclerosis.
    Marastoni D; Magliozzi R; Bolzan A; Pisani AI; Rossi S; Crescenzo F; Montemezzi S; Pizzini FB; Calabrese M
    Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34588298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma C3 and C3a levels in cryptogenic and large-vessel disease stroke: associations with outcome.
    Stokowska A; Olsson S; Holmegaard L; Jood K; Blomstrand C; Jern C; Pekna M
    Cerebrovasc Dis; 2011; 32(2):114-22. PubMed ID: 21709409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased soluble C5b-9 in CSF of neuromyelitis optica.
    Wang H; Wang K; Wang C; Qiu W; Lu Z; Hu X
    Scand J Immunol; 2014 Feb; 79(2):127-30. PubMed ID: 24313854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desensitization with antigen-specific immunoadsorption interferes with complement in ABO-incompatible kidney transplantation.
    Biglarnia AR; Nilsson B; Nilsson Ekdahl K; Tufveson G; Nilsson T; Larsson E; Wadström J
    Transplantation; 2012 Jan; 93(1):87-92. PubMed ID: 22113493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid C3a increases with age, but does not increase further in Alzheimer's disease.
    Loeffler DA; Brickman CM; Juneau PL; Perry MF; Pomara N; Lewitt PA
    Neurobiol Aging; 1997; 18(5):555-7. PubMed ID: 9390784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idebenone does not inhibit disability progression in primary progressive MS.
    Kosa P; Wu T; Phillips J; Leinonen M; Masvekar R; Komori M; Wichman A; Sandford M; Bielekova B
    Mult Scler Relat Disord; 2020 Oct; 45():102434. PubMed ID: 32784117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
    Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E
    J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune complexes and the complement factors C4 and C3 in cerebrospinal fluid and serum from patients with chronic progressive multiple sclerosis.
    Jans H; Heltberg A; Zeeberg I; Kristensen JH; Fog T; Raun NE
    Acta Neurol Scand; 1984 Jan; 69(1):34-8. PubMed ID: 6702418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The natural history of early versus late disability accumulation in primary progressive MS.
    Koch MW; Greenfield J; Javizian O; Deighton S; Wall W; Metz LM
    J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):615-21. PubMed ID: 25091366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis.
    Fissolo N; Benkert P; Sastre-Garriga J; Mongay-Ochoa N; Vilaseca-Jolonch A; Llufriu S; Blanco Y; Hegen H; Berek K; Perez-Miralles F; Rejdak K; Villar LM; Monreal E; Alvarez-Lafuente R; Soylu OK; Abdelhak A; Bachhuber F; Tumani H; Martínez-Yélamos S; Sánchez-López AJ; García-Merino A; Gutiérrez L; Castillo-Trivino T; Lycke J; Rosenstein I; Furlan R; Filippi M; Téllez N; Ramió-Torrentà L; Lünemann JD; Wiendl H; Eichau S; Khalil M; Kuhle J; Montalban X; Comabella M
    J Neurol Neurosurg Psychiatry; 2024 Apr; 95(5):410-418. PubMed ID: 37940409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.